Profil
Timothy Perera is associated with two companies as the founder.
He was the Chief Executive Officer of OCTIMET Oncology NV in 2016 and was previously the Chief Executive Officer & Director of DeuterOncology SA since its founding in 2020.
Aktive Positionen von Timothy Perera
Unternehmen | Position | Beginn |
---|---|---|
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | Gründer | 01.09.2020 |
Ehemalige bekannte Positionen von Timothy Perera
Unternehmen | Position | Ende |
---|---|---|
OCTIMET Oncology NV
OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
OCTIMET Oncology NV
OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Health Technology |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | Health Technology |